Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Functional Constipation
Phase 3
Completed
648
2024-07
Industry sponsor intelligence
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 648
Pipeline overview
Programs by phase and activity.
Velocity
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Plecanatide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. studies.
This page groups studies where Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates